TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Time to Complete Healing of Reference Ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of PD-L1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Expression of CD8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Expression of CDX2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Expression of INSM1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Expression of FOXA1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of patients with peritoneal recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Efficacy in the Treatment of TMJ and Muscle Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean daily average index knee pain while walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom alleviation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in fasting glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sense of joint position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscular electrical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postural oscillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with tumour whole genome sequencing returned within 8 weeks
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Increased daily physical activity (number of steps)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cell type and activation status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Peak Velocity Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Anxiety, Depression, and Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Functional Impairment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: MRI and MRV findings in pelvic congestion syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Muscle Size - Lower Body
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in Muscle Size - Upper Body
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Accumulation of fat in the liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tissue insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent of Sensor Glucose Values in 70-140 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in Primary Problematic Symptom (Pain or Tingling)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the score of the Hand assessment for infants (HAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the score of the Infant motor profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the score of the Alberta infant motor scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: extent of organ involvement and organ damage or dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Benign Pigmented Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Static testing of ACL reconstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative opioid analgesic dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic safety measures
Endpoint domain: Adverse events/effects
Primary endpoint: Non-vellus hair counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forced Expiratory Volume in the first second (FEV1) % predicted value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Days With a Correct Number of Doses Taken
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects achieving OARSI/OMERACT response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Plasma PF-05221304 AUClast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma PF-05221304 Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Avoidance of Neck Surgery
Endpoint domain: Adverse events/effects
Primary endpoint: PC20 Methacholine dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Median Change in Visceral Adipose Tissue (VAT) Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dietary change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Evaluable Patients With an Increase From Baseline in Hemoglobin (Hb) of ≥1.5 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Total Hemoglobin (Hb) From Baseline to Peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: percentage volume asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perioperative plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Physician's Global Assessment (PGA) Score of Cleared (0) or Minimal (1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue to Background Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asexual P. falciparum Parasite Clearance Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of early neutrophil engraftment using Myeloablative Conditioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of early neutrophil engraftment using Reduced Intensity Conditioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Parent knowledge about asthma
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Healthy behaviors to reduce breathing problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Complete Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Initiation of spontaneous labour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Plasma Lidocaine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3 year Disease Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Children and Adolescents Reaching HbA1c target <7.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of cytology and histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nutritional management effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HCV viraemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change From Baseline in Total, Basal, and Bolus Exogenous Insulin Requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Positron-emission tomography (PET) scan results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of acute severe malnutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease of exudation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of traveler's diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients adhering to the prescribed protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Headache Pain Free at 2 Hours Post Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Remission (Complete or Partial)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Sleep Disturbances
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Quality of Sleep During Therapy
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Combined Rate of Major Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Functional Dyspepsia Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AOFAS Midfoot scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: estimated blood loss during and after CS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Sexual risk behaviors
Endpoint domain: Life impact
Endpoint subdomain: Behavioral functioning
Primary endpoint: Change in Injection risk behaviors
Endpoint domain: Life impact
Endpoint subdomain: Behavioral functioning
Primary endpoint: Inadequate bowel cleansing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Keratoconus progression speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain level during IUD/IUS insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With SALT Score ≤ 20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: PASI 75 Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Count Recovery
Endpoint domain: Mortality/survival
Primary endpoint: Response Rates
Endpoint domain: Mortality/survival
Primary endpoint: renal function measured by creatinine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in KOOS4
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Repeat ambulance calls and attendances for hypoglycaemia within 14 days
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Functional Gait Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average per and postoperative PaO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Tissue Removed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: prevalence of psychosocial and behavioral aspects of survivorship
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pre-dose Concentration (Ctrough) of LUM and IVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of global tolerance assessment (dermatological assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of global tolerance assessment (ophthalmological assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear film Break Up Time (BUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Erectile dysfunction as measured by IIEF scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in carriage of resistant bacteria in gut and/or nose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Physician Global Assessment (PGA) of Disease Status at Month 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant Symptomatic Arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Trial recruitment feasibility
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of training procedures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Relapse of childhood acute lymphoblastic leukemia
Endpoint domain: Mortality/survival
Primary endpoint: Reduced Alcohol Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time needed to close skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cosmetic outcome after healing
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in anxiety report
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recovery rate of rFVIII activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac Damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulse wave arrival time difference between finger and toe
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success of rhythm control therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of graft patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cumulative dose of inopressors per kg bodyweight/hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Agreement
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Best Overall Objective Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of the diagnostic test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Pregnant Women Reporting Related Serious Adverse Events (SAEs) and Unrelated SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Concentration (GMC) of Serum IgG Antibodies to Pertussis Toxin (PT) in Infants Born to Women Receiving BOOSTRIX or Td
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in AI System performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exertional dyspnea intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood loss per hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Serious Adverse Experiences (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titers (GMT) of Serum Anti-rotavirus Immunoglobulin A (IgA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Swallowing evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Voice production
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ICU admission reason related to immunotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity [AUC(0-∞)] of Baricitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free Survival (PFS) Rate at Month 4
Endpoint domain: Mortality/survival
Primary endpoint: Maximum Tolerated Dose (MTD) of MM-121
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Paclitaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of droplets spread on investigator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in H Reflex Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in M wave Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnostic accuracy of FFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nominal change in FDG uptake of fat tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Disease burden
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline scores of the Cyber Bullying Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline scores of the Online Sexual Solicitation and Interaction of Minors with Adults Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline scores of the Sexting questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Toll-like receptor 4 positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change from baseline body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants With at Least a 1-point Improvement on AIHS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GVHD Incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Visceral GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area Under The Concentration-Time Curve (AUC) of Maraviroc
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain during intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of Participants With an Average of 3 or More Spontaneous Complete Bowel Movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Annualized Rate Of Change In Measured Glomerular Filtration Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Annualized Rate Of Change In eGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from baseline of sagittal and rotational knee laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: medium and long-term outcome of patients treated for childhood acute leukemia
Endpoint domain: Mortality/survival
Primary endpoint: incidence of graft failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Gastrointestinal Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 6 Minute walking test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinician Administered Posttraumatic Scale (CAPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of VR environments in painful dressing changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between pregnancy test results and serum hCG values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Substance-use relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Academic or social status
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Total Rescue Opioid Consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Bronchial Alveolar Lavage (BAL) Fluid Protein Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical improvement as defined by the continuous change in the Clinical Disease Activity Index (CDAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posterior wall puncture of internal jugular vein
Endpoint domain: Adverse events/effects
Primary endpoint: Referred pain induced area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Modified Fitzpatrick Wrinkle Scale (MFWS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: GVHD-free Relapse-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: NOD2 gene status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DF4 Lead Related Complication Rate
Endpoint domain: Adverse events/effects